Metastatic Renal Cell Carcinoma Change Vascularity

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Takeshi, Matayoshi, Yukihide, Sato, Yohsuke, Sato, Yujiro, Nagase, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437274/
https://www.ncbi.nlm.nih.gov/pubmed/22970402
http://dx.doi.org/10.1155/2012/654617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437274/
https://www.ncbi.nlm.nih.gov/pubmed/22970402
http://dx.doi.org/10.1155/2012/654617

Ejemplares similares